Joshi Kriti, Zacharin Margaret
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Department of Endocrinology, The Royal Children's Hospital, Parkville, Victoria, Australia.
J Pediatr Endocrinol Metab. 2018 Apr 25;31(5):577-580. doi: 10.1515/jpem-2017-0425.
Neonatal hyperthyroidism is rare, seen in infants of mothers with Graves' disease (GD), with transplacental transfer of thyroid-stimulating hormone receptor (TSHR) antibodies (TRAbs). We describe a neonate with severe hyperthyroidism due to TRAbs, born to a mother with autoimmune hypothyroidism.
A baby boy born preterm at 35 weeks had irritability, tachycardia and proptosis after birth. The mother had autoimmune hypothyroidism, from age 10, with thyroxine replacement and normal thyroid function throughout her pregnancy. She had never been thyrotoxic. There was a family history of Hashimoto's thyroiditis (HT) and GD. The baby's thyroid function on day 3 demonstrated gross thyrotoxicosis, TSH<0.01 mIU/L (normal range [NR]<10 mIU/L), free thyroxine (FT4)>77 pmol/L (20-35), free triiodothyronine (FT3) 15.4 pmol/L (4.2-8.3) and TRAb 18.4 IU/L (<1.8). The mother's TRAb was 24.7 IU/L. Thyrotoxicosis required propranolol and carbimazole (CBZ). Thyroid function normalized within 10 days. The baby was weaned off medication by 7 weeks. He remains euthyroid.
We postulate that this mother had co-existing destructive thyroiditis and thyroid-stimulating antibodies (TSAbs) and TSHR blocking antibodies (TBAb), rendering her unable to raise a thyrotoxic response to the TSAbs but with predominant TSAb transmission to her infant. Maternal history of any thyroid disorder may increase the risk of transmission to an infant, requiring a careful clinical assessment of the neonate, with important implications for future pregnancies.
新生儿甲亢较为罕见,见于患有格雷夫斯病(GD)母亲的婴儿,甲状腺刺激激素受体(TSHR)抗体(TRAbs)经胎盘转移。我们描述了一名因TRAbs导致严重甲亢的新生儿,其母亲患有自身免疫性甲状腺功能减退症。
一名35周早产男婴出生后出现易激惹、心动过速和突眼。母亲自10岁起患有自身免疫性甲状腺功能减退症,孕期一直服用甲状腺素且甲状腺功能正常。她从未出现过甲状腺毒症。有桥本甲状腺炎(HT)和GD家族史。婴儿出生第3天的甲状腺功能显示严重甲状腺毒症,促甲状腺激素(TSH)<0.01 mIU/L(正常范围[NR]<10 mIU/L),游离甲状腺素(FT4)>77 pmol/L(20 - 35),游离三碘甲状腺原氨酸(FT3)15.4 pmol/L(4.2 - 8.3),TRAb 18.4 IU/L(<1.8)。母亲的TRAb为24.7 IU/L。甲状腺毒症需要使用普萘洛尔和卡比马唑(CBZ)治疗。10天内甲状腺功能恢复正常。婴儿7周时停用药物。其甲状腺功能仍保持正常。
我们推测该母亲同时存在破坏性甲状腺炎以及甲状腺刺激抗体(TSAbs)和TSHR阻断抗体(TBAb),这使得她无法对TSAbs产生甲状腺毒症反应,但主要是TSAb传递给了她的婴儿。母亲有任何甲状腺疾病史都可能增加向婴儿传播的风险,需要对新生儿进行仔细的临床评估,这对未来的妊娠具有重要意义。